^
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 week
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive: A1 - Approval
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
NTRK1 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
cisplatin + paclitaxel + SGN-15
Sensitive: A2 - Guideline
NTRK1 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
docetaxel
Sensitive: A2 - Guideline
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive: A2 - Guideline
TMB-H
Endometrial Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
cisplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
topotecan
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
cisplatin + SGN-15
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
SGN-15
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
temsirolimus
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
bevacizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A2 - Guideline
NTRK3 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
tamoxifen + medroxyprogesterone
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
tamoxifen
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
fulvestrant
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
medroxyprogesterone
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
megestrol
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
tamoxifen + megestrol
Sensitive: A2 - Guideline
No biomarker
Endometrial Cancer
everolimus + letrozole
Sensitive: A2 - Guideline
CTNNB1 mutation
Endometrial Cancer
PRI-724 + SM04690
Sensitive: B - Late Trials
CTNNB1 mutation
Endometrial Cancer
SM04690
Sensitive: B - Late Trials
HER-2 overexpression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
BRCA1 mutation
Endometrial Cancer
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Endometrial Cancer
olaparib
Sensitive: C1 - Off-label
KRAS G12C
Endometrial Cancer
sotorasib
Sensitive: C1 - Off-label
KIT expression
Endometrial Cancer
imatinib
Sensitive: C1 - Off-label
HER-2 overexpression
Endometrial Cancer
trastuzumab
Sensitive: C1 - Off-label
BRCA1 mutation
Endometrial Cancer
niraparib
Sensitive: C1 - Off-label
MSI-H/dMMR
Endometrial Cancer
INCMGA0012
Sensitive: C2 – Inclusion Criteria
ER positive
Endometrial Cancer
ribociclib + letrozole
Sensitive: C2 – Inclusion Criteria
POLE mutation
Endometrial Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
FGFR2 S252W
Endometrial Cancer
ponatinib
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Endometrial Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
POLE mutation
Endometrial Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Endometrial Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Endometrial Adenocarcinoma
AZD1775
Sensitive: C3 – Early Trials
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C3 – Early Trials
ER positive
Endometrial Cancer
palbociclib + letrozole
Sensitive: C3 – Early Trials
DKK1 overexpression
Endometrial Cancer
DKN-01
Sensitive: C3 – Early Trials
MCL1 amplification
Endometrial Cancer
CYC065
Sensitive: C3 – Early Trials
KRAS G12C
Endometrial Cancer
MRTX849
Sensitive: C3 – Early Trials
ATM PI2629fs*
Endometrial Cancer
BAY1895344
Sensitive: C3 – Early Trials
FOLR1 expression
Endometrial Cancer
IMGN 853
Sensitive: C3 – Early Trials
PD-L1 expression
Endometrial Cancer
AB122
Sensitive: C3 – Early Trials
TMB-H
Endometrial Cancer
AB122
Sensitive: C3 – Early Trials
POLE V411L
Endometrial Cancer
nivolumab
Sensitive: C3 – Early Trials
POLE P286R
Endometrial Cancer
nivolumab
Sensitive: C3 – Early Trials
PTEN mutation
Endometrial Cancer
LY3023414
Sensitive: C3 – Early Trials
PIK3R1 mutation
Endometrial Cancer
LY3023414
Sensitive: C3 – Early Trials
BRCA1 mutation
Endometrial Cancer
rucaparib + sacituzumab govitecan-hziy
Sensitive: C3 – Early Trials
KRAS mutation
Endometrial Cancer
VS-6766
Sensitive: C3 – Early Trials
PTEN-L
Endometrial Cancer
cobimetinib + GDC-0068
Sensitive: C3 – Early Trials
KRAS mutation
Endometrial Cancer
cobimetinib + GDC-0068
Sensitive: C3 – Early Trials
HER-2 expression
Endometrial Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
AKT1 mutation
Endometrial Cancer
temsirolimus
Sensitive: C3 – Early Trials
CTNNB1 mutation
Endometrial Cancer
everolimus + letrozole
Sensitive: C3 – Early Trials
CTNNB1 mutation
Endometrial Cancer
temsirolimus
Sensitive: C3 – Early Trials
EGFR E690K
Endometrial Cancer
lapatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Endometrial Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
KRAS mutation
Endometrial Cancer
BGB-283
Sensitive: C3 – Early Trials
PTEN deletion
Endometrial Cancer
olaparib
Sensitive: C3 – Early Trials
TSC1 mutation
Endometrial Cancer
temsirolimus
Sensitive: C3 – Early Trials
TSC2 mutation
Endometrial Cancer
temsirolimus
Sensitive: C3 – Early Trials
FGFR2-BICC1 fusion
Endometrial Cancer
erdafitinib
Sensitive: C3 – Early Trials
FGFR2-OFD1 fusion
Endometrial Cancer
erdafitinib
Sensitive: C3 – Early Trials
LRP1B mutation
Endometrial Cancer
pembrolizumab
Sensitive: C3 – Early Trials
LRP1B mutation
Endometrial Cancer
nivolumab
Sensitive: C3 – Early Trials
HER-2 amplification
Endometrial Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Endometrial Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Endometrial Cancer
pyrotinib
Sensitive: C3 – Early Trials
MSH2 deletion
Endometrial Cancer
nivolumab
Sensitive: C3 – Early Trials
MLH1 deletion
Endometrial Cancer
nivolumab
Sensitive: C3 – Early Trials